Dean J. Mitchell - 14 Jun 2023 Form 4 Insider Report for ImmunoGen, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 14 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2023, 16:46:47 UTC
Prior SEC filing: 14 Jun 2023
Next SEC filing: 26 Sep 2023
Source filing: View source filing
Reporting owner signature: /s/ Renee Lentini, Attorney-in-Fact

Key filing fact

Dean J. Mitchell filed Form 4 for ImmunoGen, Inc. on 16 Jun 2023.

Key facts

This page summarizes Dean J. Mitchell's Form 4 filing for ImmunoGen, Inc..
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Jun 2023, 16:46.

Change

Previous filing in this sequence was filed on 14 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMGN transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +13,090
Change %
Price: $0.000000
Shares after: 13,090
Date: 14 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,090
Exercise price: $0.000000
Footnotes: F1, F2

IMGN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +19,597
Change %
Price: $0.000000
Shares after: 19,597
Date: 14 Jun 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,597
Exercise price: $17.72
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The restricted stock units ("RSUs") were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended. Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.

Footnote F2

The restricted stock units vest on the one-year anniversary of the date of grant, contingent upon the individual remaining a director as of the vesting date.

Footnote F3

The stock options were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors, as amended, and the 2018 Employee, Director and Consultant Equity Incentive Plan, as amended.

Footnote F4

The stock options vest ratably on each of 9/1/23, 12/1/23, 3/1/24, and 6/1/24, contingent upon the individual remaining a director as of each vesting date.